PharmaCyte Biotech, Inc.
PMCBHealthcare|Biotechnology|US
$0.36
-0.02 (-4.05%)
DCF Value
$2.22
Tangible Book / Share
$2.78
Cash / Share
$2.84
Financials
Financial Snapshot
Market Cap
$3.9M
Enterprise Value
-$13.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$16.1M
Cash & Investments
$30.5M
Net Cash
$30.5M
Free Cash Flow (TTM)
-$3.9M
Operating CF (TTM)
-$3.9M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$30.5M
Quarterly Burn
$985.0K
Monthly Burn
$328.3K
Est. Runway
~31.0 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.5M | $1.1M | $515.3K | $894.9K | $2.2M | $85.4M | $68.0M | $50.2M | $15.5M | $37.1M | $30.5M | |
| Operating Cash Flow | -$3.3M | -$5.1M | -$2.9M | -$2.3M | -$3.3M | -$4.1M | -$3.8M | -$2.2M | -$3.0M | -$5.2M | -$3.9M | |
| Free Cash Flow | -$3.3M | -$5.1M | -$2.9M | -$2.3M | -$3.3M | -$4.1M | -$3.8M | -$2.2M | -$3.0M | -$5.2M | -$3.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $4.9M | $2.7M | $2.3M | $2.7M | $4.6M | $87.3M | -$13.6M | -$10.7M | -$25.0M | $6.6M | $6.5M |
R&D Spending
R&D (TTM)
$356.1K
R&D Intensity
—
R&D Growth vs Prior
-9.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.2M | $2.0M | $460.1K | $301.2K | $916.2K | $690.9K | $468.5K | $407.4K | $438.4K | $391.3K | $356.1K | |
| SG&A | $3.3M | $5.0M | $3.6M | $3.5M | $418.1K | $2.2M | $4.8M | $6.1M | $3.9M | $4.9M | $5.1M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $1.2M | $2.0M | $460.1K | $301.2K | $916.2K | $690.9K | $468.5K | $407.4K | $438.4K | $391.3K | $356.1K | |
| SG&A | $3.3M | $5.0M | $3.6M | $3.5M | $418.1K | $2.2M | $4.8M | $6.1M | $3.9M | $4.9M | $5.1M | |
| Operating Income | -$4.4M | -$7.0M | -$4.1M | -$3.8M | -$3.6M | -$4.4M | -$6.5M | -$8.5M | -$4.4M | -$6.9M | -$7.0M | |
| Interest Expense | $1.5K | $0.00 | $0.00 | $453.00 | $3.0K | $509.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$4.4M | -$6.8M | -$4.1M | -$3.8M | -$3.6M | -$4.2M | -$4.3M | $333.8K | $30.7M | -$19.4M | -$16.1M | |
| Net Income | -$4.4M | -$6.8M | -$4.1M | -$3.8M | -$3.6M | -$4.2M | -$4.3M | $333.8K | $30.7M | -$19.4M | -$16.1M | |
| EPS (Diluted) | -15.00 | -15.00 | -5.55 | -4.23 | -2.45 | -0.27 | -0.22 | -1.80 | 3.19 | -2.77 | -2.41 | |
| EBITDA | $146.00 | -$7.0M | -$4.1M | -$3.8M | -$3.5M | -$4.2M | -$6.5M | -$6.5M | -$4.4M | -$5.3M | -$5.5M | |
| Shares Out. (M) | 0.56 | 0.65 | 0.73 | 0.90 | 1.45 | 15.52 | 19.49 | 9.58 | 7.33 | 8.38 | 10.74 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.5M | $1.1M | $515.3K | $894.9K | $2.2M | $85.4M | $68.0M | $50.2M | $15.2M | $18.6M | $17.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $366.3K | $18.5M | $12.8M | |
| Total Current Assets | $3.5M | $1.3M | $653.4K | $1.0M | $2.3M | $85.5M | $68.1M | $50.4M | $22.4M | $37.4M | $31.0M | |
| Total Assets | $8.7M | $6.4M | $5.8M | $6.2M | $7.4M | $90.6M | $73.3M | $59.9M | $55.2M | $46.8M | $36.7M | |
| Total Current Liabilities | $580.2K | $644.2K | $742.9K | $1.0M | $724.8K | $704.4K | $586.6K | $7.4M | $2.9M | $826.4K | $768.7K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $46.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $580.2K | $644.2K | $742.9K | $1.1M | $724.8K | $704.4K | $586.6K | $20.4M | $3.3M | $11.8M | $6.9M | |
| Stockholders' Equity | $8.1M | $5.8M | $5.0M | $5.1M | $6.7M | $89.9M | $72.7M | $39.5M | $51.9M | $33.3M | $29.8M | |
| Retained Earnings | -$89.1M | -$96.0M | -$100.0M | -$103.9M | -$107.4M | -$111.6M | -$116.0M | -$115.6M | -$85.0M | -$104.4M | -$109.5M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M | -$5.1M | -$2.9M | -$2.3M | -$3.3M | -$4.1M | -$3.8M | -$2.2M | -$3.0M | -$5.2M | -$3.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$3.3M | -$5.1M | -$2.9M | -$2.3M | -$3.3M | -$4.1M | -$3.8M | -$2.2M | -$3.0M | -$5.2M | -$3.9M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.0M | -$7.0M | $2.0M | $2.0M | |
| Financing Cash Flow | $4.9M | $2.7M | $2.3M | $2.7M | $4.6M | $87.3M | -$13.6M | -$10.7M | -$25.0M | $6.6M | $6.5M | |
| Issuance of Stock | $4.9M | $2.7M | $2.3M | $2.7M | $4.7M | $87.4M | $880.00 | $33.7M | $0.00 | $1.0M | $1.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$13.6M | -$44.4M | -$25.0M | -$401.6K | -$401.6K | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $62.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.0M | $1.5M | $705.7K | $748.0K | $370.8K | $78.0K | $645.4K | $674.7K | $478.6K | $1.1M | $1.1M | |
| Net Change in Cash | $1.5M | -$2.4M | -$544.5K | $379.6K | $1.3M | $83.2M | -$17.4M | -$17.9M | -$35.0M | $3.4M | $4.6M |
Dilution Tracker
Shares outstanding grew 478.5% over 5 years — significant dilution
Shares Outstanding
11M
5-Year Share Growth
+478.5%
Stock Issuance (TTM)
$1.0M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.56 | 0.65 | 0.73 | 0.90 | 1.45 | 15.52 | 19.49 | 9.58 | 7.33 | 8.38 | 10.74 | |
| Change vs Prior % | — | 14.6% | 13.6% | 23.2% | 60.2% | 971.7% | 25.6% | -50.8% | -23.5% | 14.3% | 28.1% | |
| Stock Issuance | $4.9M | $2.7M | $2.3M | $2.7M | $4.7M | $87.4M | $880.00 | $33.7M | $0.00 | $1.0M | $1.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$13.6M | -$44.4M | -$25.0M | -$401.6K | -$401.6K | |
| Stock Based Comp. | $1.0M | $1.5M | $705.7K | $748.0K | $370.8K | $78.0K | $645.4K | $674.7K | $478.6K | $1.1M | $1.1M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -55.0% | -118.4% | -80.7% | -75.2% | -53.2% | -4.7% | -5.9% | 0.8% | 59.1% | -58.3% | -46.4% | |
| ROA % | -51.3% | -106.5% | -70.3% | -62.1% | -48.0% | -4.7% | -5.9% | 0.6% | 55.6% | -41.5% | -44.0% | |
| ROIC % | -54.9% | -121.0% | -81.4% | -74.1% | -54.2% | -4.9% | -8.9% | -16.2% | -8.4% | -14.9% | -19.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 26.9% | -57.2% | 41.3% | 6.7% | 5.3% | -21.2% | -47.0% | -32.0% | 48.6% | -56.6% | |
| Net Income | 26.7% | -53.7% | 40.4% | 5.9% | 7.2% | -19.4% | -1.8% | 107.7% | 9085.0% | -163.4% | |
| EPS (Diluted) | 0.0% | 0.0% | 63.0% | 23.8% | 42.1% | 89.0% | 18.5% | -718.2% | 277.2% | -186.8% | |
| Operating Cash Flow | 23.2% | -52.1% | 43.3% | 18.7% | -42.4% | -23.6% | 7.9% | 43.3% | -38.4% | -73.0% | |
| Free Cash Flow | 23.2% | -52.1% | 43.3% | 18.7% | -42.4% | -23.6% | 7.9% | 43.3% | -38.4% | -73.0% | |
| R&D Expense | -16.0% | 69.0% | -77.0% | -34.5% | 204.2% | -24.6% | -32.2% | -13.0% | 7.6% | -10.7% | |
| SG&A Expense | -30.1% | 52.9% | -26.9% | -3.2% | -88.1% | 415.7% | 120.4% | 28.6% | -35.6% | 24.7% | |
| Total Assets | 21.0% | -26.0% | -9.8% | 6.6% | 20.1% | 1124.0% | -19.1% | -18.3% | -7.9% | -15.3% | |
| Book Value / Share | 69.2% | -53.6% | -45.8% | -18.0% | -18.1% | 25.6% | -35.6% | 5626.6% | -96.7% | -29.5% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 12.3% | 14.6% | 13.6% | 23.2% | 60.2% | 971.7% | 25.6% | -50.8% | -23.5% | 14.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.13
10Y Low / Med / High0.01 / 4.16 / 9.24
EV/EBITDA2.54
10Y Low / Med / High1.39 / 7.64 / 206929.39
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$2.22
Tangible Book / Share
$2.78
Net Current Assets / Share
$2.24
Graham Net-Net
$2.23
Cash / Share
$2.84
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -14.44 | -7.92 | -11.45 | -8.98 | -11.20 | -8.63 | -13.27 | -1.18 | 0.39 | -0.26 | -0.15 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 4.16 | 6.60 | 9.24 | 6.74 | 5.95 | 0.40 | 0.78 | 0.01 | 0.18 | 0.15 | 0.13 | |
| EV/EBITDA | 206929.39 | -5.30 | -11.23 | -8.75 | -10.57 | 11.62 | 1.72 | 7.64 | 1.39 | 2.55 | 2.54 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-3.34
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$377.0M | -$2.0M | -$2.7M |
| EPS | $-45.00 | $-0.24 | $-0.32 |
| # Analysts (EPS) | 1 | 1 | 1 |